{"id":3690,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2021-07-15","marketCap":676.5897827148438,"name":"Erasca Inc","phone":"18584656511","outstanding":173.36000061035156,"symbol":"ERAS","website":"https://www.erasca.com/","industry":"Biotechnology"},"price":2.4375,"year":2024,"month":5,"day":31,"weekday":"Friday","title":"The Influence of Geopolitical Events on Erasca Inc Stock Markets","date":"2024-05-31","url":"/posts/2024/05/31/ERAS","content":[{"section":"Introduction","text":"Geopolitical events can have a significant influence on stock markets, including that of Erasca Inc. These events encompass political, economic, and social factors that affect the global landscape and can create uncertainty for investors."},{"section":"Trade Wars","text":"Trade wars, such as the ongoing tensions between the United States and China, can have a direct impact on Erasca Inc's stock markets. Increased tariffs and trade barriers can disrupt global supply chains and create uncertainties for businesses, leading to potential declines in stock prices."},{"section":"Political Stability","text":"Political stability is crucial for stock market performance. Geopolitical events like elections or political unrest can create volatility and uncertainty, which may adversely affect Erasca Inc's stock prices. Stable political conditions, on the other hand, can provide a favorable environment for market growth."},{"section":"Economic Sanctions","text":"The imposition of economic sanctions by one country on another can impact Erasca Inc's stock markets. Sanctions can restrict business operations, hinder trade, and limit access to essential resources, potentially leading to a decline in stock prices."},{"section":"Global Economic Events","text":"Significant global economic events, such as recessions, financial crises, or changes in interest rates, can have indirect effects on Erasca Inc's stock markets. Economic downturns may lower investor confidence, leading to market declines, while positive economic indicators can drive market growth."},{"section":"Regional Conflicts and Security Concerns","text":"Regional conflicts and security concerns, such as military conflicts or terrorist activities, can create instability in the global landscape. These events can lead to increased risk aversion among investors and potentially cause declines in Erasca Inc's stock prices."},{"section":"Market Sentiment","text":"Geopolitical events influence market sentiment, which can impact Erasca Inc's stock markets. Positive geopolitical developments, such as international agreements or diplomatic breakthroughs, can improve investor confidence and drive market growth. Conversely, negative events may dampen investor sentiment and lead to market declines."},{"section":"Conclusion","text":"Geopolitical events have the potential to significantly influence Erasca Inc's stock markets. Factors such as trade wars, political stability, economic sanctions, global economic events, regional conflicts, and market sentiment all contribute to the volatility and performance of the company's stock prices. Investors should consider such events when making investment decisions related to Erasca Inc."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1716984000,"headline":"Erasca to Present at Upcoming Investor Conferences in June","id":127970965,"image":"https://s.yimg.com/ny/api/res/1.2/nrlmh4JJBt.m_15lf4tHGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xOTY-/https://media.zenfs.com/en/globenewswire.com/5c8ec1fd7d054e86d736c74dd62cf21c","symbol":"ERAS","publisher":"Yahoo","summary":"SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one","url":"https://finance.yahoo.com/news/erasca-present-upcoming-investor-conferences-120000963.html"},{"category":"company","date":1716462044,"headline":"Independent Director of Erasca Picks Up 14% More Stock","id":127870904,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ERAS","publisher":"Yahoo","summary":"Investors who take an interest in Erasca, Inc. ( NASDAQ:ERAS ) should definitely note that the Independent Director...","url":"https://finance.yahoo.com/news/independent-director-erasca-picks-14-110044844.html"},{"category":"company","date":1716456480,"headline":"Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers","id":127865924,"image":"","symbol":"ERAS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3509128920"},{"category":"company","date":1716456480,"headline":"e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday","id":127865087,"image":"","symbol":"ERAS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3509129657"},{"category":"company","date":1716455400,"headline":"Jaguar Health, Altamira Therapeutics,Erasca among healthcare movers","id":127865926,"image":"","symbol":"ERAS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3509105306"},{"category":"company","date":1716450780,"headline":"$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying","id":127871187,"image":"","symbol":"ERAS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3509009586"},{"category":"company","date":1716374350,"headline":"Erasca : Investor Update May 2024","id":127838806,"image":"","symbol":"ERAS","publisher":"Finnhub","summary":"On a Journey to Erase Cancer Erasca Investor Update May 2024 ...","url":"https://finnhub.io/"},{"category":"company","date":1716321900,"headline":"Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares","id":127834296,"image":"https://s.yimg.com/ny/api/res/1.2/nrlmh4JJBt.m_15lf4tHGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xOTY-/https://media.zenfs.com/en/globenewswire.com/5c8ec1fd7d054e86d736c74dd62cf21c","symbol":"ERAS","publisher":"Yahoo","summary":"SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional share","url":"https://finance.yahoo.com/news/erasca-announces-closing-underwritten-offering-200500093.html"},{"category":"company","date":1716208500,"headline":"Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal","id":127797369,"image":"","symbol":"ERAS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503613066"},{"category":"company","date":1716182220,"headline":"Erasca’s Promising Pipeline and Solid Funding Outlook Balanced by Caution: A Hold Rating","id":127797458,"image":"","symbol":"ERAS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503788536"},{"category":"company","date":1716181920,"headline":"Erasca price target lowered by $3 at H.C. Wainwright, here's why","id":127797459,"image":"","symbol":"ERAS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503784066"},{"category":"company","date":1716170160,"headline":"Erasca’s Strategic Advances and Financial Fortitude Merit a Buy Rating","id":127818511,"image":"","symbol":"ERAS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3504340513"},{"category":"company","date":1716167880,"headline":"Optimistic Outlook for Erasca: Strategic Growth and Financial Prudence","id":127797460,"image":"","symbol":"ERAS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503639330"},{"category":"company","date":1716115560,"headline":"Erasca Inc. Earns Buy Rating: Strategic Acquisitions and Promising Pipeline Positioning","id":127797461,"image":"","symbol":"ERAS","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503547462"},{"category":"company","date":1715943060,"headline":"What You Missed On Wall Street This Morning","id":127756899,"image":"","symbol":"ERAS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500651475"},{"category":"company","date":1715942650,"headline":"Erasca : Corporate Presentation May 2024","id":127755769,"image":"","symbol":"ERAS","publisher":"Finnhub","summary":"On a Journey to Erase Cancer Erasca Investor Update May 2024 ...","url":"https://finnhub.io/"},{"category":"company","date":1715939460,"headline":"Erasca restructures; Novartis moves to complete MorphoSys deal","id":127756973,"image":"https://www.biopharmadive.com/imgproxy/M-9XUfwmU8uQjJH7R2jIk5LnPYxLd5pzDssaXMhRTMc/crop:6097:3444/g:nowe:909:0/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0ODM5MjE3OTMuanBn.webp","symbol":"ERAS","publisher":"Yahoo","summary":"The cancer biotech is laying off one-fifth of its staff and scrapping three drugs. Elsewhere, Novartis secured sufficient support for its $3B buyout and Bristol Myers won a new CAR-T approval.","url":"https://www.biopharmadive.com/news/erasca-layoffs-breyanzi-approval-morphosys-novartis/716290/"},{"category":"company","date":1715939040,"headline":"Erasca stock climbs 10% amid pipeline restructuring, equity offering","id":127760992,"image":"","symbol":"ERAS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500570247"},{"category":"company","date":1715920680,"headline":"DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session","id":127757653,"image":"","symbol":"ERAS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500268892"},{"category":"company","date":1715915460,"headline":"What You Missed On Wall Street On Friday","id":127764756,"image":"","symbol":"ERAS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500978395"},{"category":"company","date":1715912040,"headline":"Erasca prices $160M equity offering","id":127760995,"image":"","symbol":"ERAS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500159531"},{"category":"company","date":1715904120,"headline":"Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise","id":127760928,"image":"https://s.yimg.com/ny/api/res/1.2/nrlmh4JJBt.m_15lf4tHGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xOTY-/https://media.zenfs.com/en/globenewswire.com/5c8ec1fd7d054e86d736c74dd62cf21c","symbol":"ERAS","publisher":"Yahoo","summary":"Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERA","url":"https://finance.yahoo.com/news/erasca-announces-strategic-licensing-ras-000200201.html"},{"category":"company","date":1715904000,"headline":"Erasca Announces Pricing of Underwritten Offering of Common Stock","id":127760929,"image":"https://s.yimg.com/ny/api/res/1.2/nrlmh4JJBt.m_15lf4tHGg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xOTY-/https://media.zenfs.com/en/globenewswire.com/5c8ec1fd7d054e86d736c74dd62cf21c","symbol":"ERAS","publisher":"Yahoo","summary":"SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before d","url":"https://finance.yahoo.com/news/erasca-announces-pricing-underwritten-offering-000000856.html"}]}